Microbiome

Exploitation of microbiome science will unlock multiple commercial opportunities across a number of industries including life sciences. But there is a need for more effective data and process management to get the best from microbiome data, according to Dr Sven Sewitz, Director of Biodata Innovation at Eagle Genomics. The microbiome comprises trillions of diverse bacteria […]

Genetic Analysis has announced a Service Agreement with Eurofins ADME Bioanalysis, a CRO who have launched a standardised gut microbiome test (GA-map Dysbiosis Test).  Gut microbiome profiling is required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due to both the impact new pharmaceuticals can have on microbiomes and the fact that the […]

This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is titled “Precision control of protein release to reconfigure bioprocessing and cell-based assays”, where the authors Dr […]

Microbiome experts from Microba Life Sciences will discuss the next phase of discovery from the microbiome to a global audience via a series of webinars on September 15 (PST 10am-12pm | EST 1-3pm | CET 7pm).  Professor Gene Tyson, Associate Professor Lutz Krause and Dr Alena Pribyl will discuss how advancements in metagenomic analysis techniques are revealing novel biomarkers and relationships […]

CN Bio has licenced a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University to investigate the direct interaction between the microbiome and gut and the wider effects of the microbiome on organs such as the liver and brain. Planned for commercial launch in 2023, the technology […]

GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is a space with high potential, […]

King’s College London is using CNBio’s PhysioMimix Multi-Organ MPS. Following a research collaboration, King’s College London selected the system to create a human-relevant liver-intestinal model for characterising and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, the product combines CN Bio’s in vitro 3D liver model with a range of […]

Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an easy to use, in vitro […]

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial […]

Children under age two  who take antibiotics are at greater risk for childhood-onset asthma, respiratory allergies, eczema, coeliac disease, obesity and attention deficit hyperactivity disorder, according to a paper written jointly by Mayo Clinic and Rutgers researchers. In a study published in the journal Mayo Clinic Proceedings, the researchers looked at 14,572 children in Olmsted […]